Last update 26 Dec 2024

SNC-109

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
SNC 109, SNC109
Target
EGFR x EGFRvIII x HER2 x IL-13Rα2
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), EGFRvIII antagonists(Epidermal growth factor receptor variant III antagonists), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists)
Therapeutic Areas
NeoplasmsNervous System DiseasesOther Diseases
Active Indication
Glioblastoma MultiformeRecurrent Glioblastoma
Inactive Indication-
Originator Organization
Shanghai Simnova Biotechnology Co.,Ltd.
Active Organization
Shanghai Simnova Biotechnology Co.,Ltd.
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

Related

3
Clinical Trials associated with SNC-109
NCT06616727 / Enrolling by invitationPhase 1
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SNC109 in Patients With Recurrent Glioblastoma
NCT05868083 / RecruitingPhase 1
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of SNC-109 CAR-T Cell Therapy in Subjects With Recurrent Glioblastoma
CTR20243306 / Not yet recruitingPhase 1
一项在复发胶质母细胞瘤受试者中评估SNC109注射液的安全性、耐受性和药代动力学的I期临床研究
[Translation] A Phase I clinical study evaluating the safety, tolerability and pharmacokinetics of SNC109 injection in subjects with recurrent glioblastoma
100 Clinical Results associated with SNC-109
Login to view more data
100 Translational Medicine associated with SNC-109
Login to view more data
100 Patents (Medical) associated with SNC-109
Login to view more data
100 Deals associated with SNC-109
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Glioblastoma MultiformePhase 1
CN
Shanghai Simnova Biotechnology Co.,Ltd.
26 Dec 2023
Recurrent GlioblastomaPhase 1
CN
Shanghai Simnova Biotechnology Co.,Ltd.
24 Jun 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free